efficacy

There is increasing concern that reducing carbon emissions alone will not be sufficient to stabilize the climate and that technologies that actively remove carbon dioxide from the air will be needed. There has been a fair amount of analysis of the efficacy of storing carbon in agricultural soil and in forests, but there has not been comparable studies of the risks, benefits, and trade-offs of ocean-based strategies.

The oceans currently absorb about a quarter of the world’s carbon dioxide emissions. There are multiple ways in which oceans could be induced to store much more. A new report from the National Academies of Sciences, Engineering, and Medicine looks at several ocean carbon dioxide removal strategies in terms of efficacy, potential costs, and potential environmental risks.

One approach involves adding nutrients to the ocean surface to increase photosynthesis by phytoplankton. The approach has a medium to high chance of being effective and has medium environmental risks.

Another approach is large-scale seaweed farming that transports carbon to the deep ocean or into sediments. It has medium efficacy chances but higher environmental risks.

Protection and restoration of coastal ecosystems including marine wildlife would have the lowest environmental risk but only low to medium efficacy.

Chemically altering ocean water to increase its alkalinity in order to enhance reactions that take up carbon dioxide would be highly effective but a medium environmental risk.

The report describes some other approaches as well. It recommends a $125 million research program to better understand the technological challenges as well as the potential economic, social, and environmental impacts of increasing the oceans’ absorption of carbon dioxide.

**********

Web Links

Oceans Could Be Harnessed to Remove Carbon From Air, Say U.S. Science Leaders

Photo, posted August 21, 2016, courtesy of Quinn Dombrowski via Flickr.

Earth Wise is a production of WAMC Northeast Public Radio.

Malaria is a parasitic disease transmitted through the bite of female Anopheles mosquitoes. Although the disease is both preventable and treatable, an estimated 435,000 people die of it each year, with the majority being children younger than five. Over 90% of all malaria cases and deaths occur in Africa.

The battle against malaria has mostly centered around the use of bed nets, insecticide spraying and antimalarial drugs. To date, there has not been an effective malaria vaccine available.

That may finally be changing. The first vaccinations have begun in Mali in a phase III trial of a malaria vaccine developed by the University of Oxford. The Oxford vaccine showed an efficacy of 77% over 12 months in a phase IIb trial and the hope is that the phase III trial will lead to the licensing of the vaccine in 2023.

Oxford is partnering with the Serum Institute of India for the manufacturing of the vaccine in order to be able to produce high volumes of low-cost vaccine and provide access to countries where it is required the most. The Serum Institute has committed to the production of more than 200 million doses per year once the vaccine is licensed for use, which will be an adequate supply for children most at risk of malaria in sub-Saharan Africa.

The World Health Organization Malaria Vaccine Technology Roadmap has a goal of a malaria vaccine with at least 75% efficacy. Such a vaccine is needed in order to reach the WHO’s goal of reducing malaria deaths by at least 90% by 2030.

**********

Web Links

Promising malaria vaccine enters final stage of clinical testing in West Africa

Photo, posted June 9, 2018, courtesy of Mario Yordanov via Flickr.

Earth Wise is a production of WAMC Northeast Public Radio.